ViiV, which had an HIV shot pass late-stage trials earlier this year, has seen its two-drug treatment for HIV infections win approval from the U.S. Food and Drug Administration.
ViiV is GSK’s HIV drugs division where Pfizer and Shionogi & Co have stakes as well.
The FDA cleared the combo of dolutegravir and lamivudine, to be branded as Dovato, for use in newly diagnosed adults.
Last year, GSK's trials found that the once-a-day Dovato pill was as good as a standard three-drug cocktail in suppressing the virus that causes AIDS.
GSK currently has another two-drug regimen, Juluca, on the market. However, Juluca is meant for HIV patients that have received prior treatment.
Read the Reuters report.